Glyset
Glyset Price range: $ 78,00 through $ 156,00
Back to products
Gyne-Lotrimin
Gyne-Lotrimin Price range: $ 40,00 through $ 63,00

Grifulvin V

Price range: $ 30,00 through $ 292,00

Grifulvin V is a specialized antifungal medication designed to treat a variety of fungal infections affecting the skin, hair, and nails. This treatment is highly effective against common conditions such as ringworm, athlete’s foot, and jock itch. By inhibiting the growth of fungal cells, the active ingredient helps to stop the spread of the infection at its source. It is particularly useful for managing persistent infections in the scalp and nail beds where topical creams may not be sufficient. Regular use of Grifulvin V supports the restoration of healthy skin and promotes the regrowth of clear, unaffected nails.

Active substance: Griseofulvin
SKU: Grifulvin V Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Grifulvin V belongs to the class of systemic antifungal medications containing microsize griseofulvin as its active substance. It is prescribed by licensed healthcare providers in the United States for treating fungal infections of the skin, hair, and nails that do not respond adequately to topical antifungal therapies.

Because Grifulvin V is classified as a prescription-only (Rx) medication under federal FDA regulations, its administration requires appropriate medical evaluation, individualized dosing, and regular laboratory monitoring when used for extended therapeutic durations.

Attribute Details
Active Ingredient Griseofulvin (microsize)
Therapeutic Class Systemic Antifungal Agent
Dosage Form Oral Tablet / Oral Suspension
Prescription Status Prescription Only (Rx)
Primary Indication Dermatophyte fungal infections (skin, scalp, nails)
Key Requirement Take with or after high-fat meals for optimal absorption

How the drug works

Grifulvin V exerts its therapeutic effect through a fungistatic mechanism that disrupts the structural integrity of susceptible fungal organisms. The active component, microsize griseofulvin, selectively binds to fungal tubulin, a structural protein required for microtubule assembly. By inhibiting microtubule polymerization, the medication arrests fungal cell division in metaphase, preventing the organism from replicating and spreading through host tissues.

In addition to cell division arrest, Grifulvin V exhibits a unique tissue-specific localization. After systemic absorption, the drug selectively deposits in keratin precursor cells within the basal layers of the skin, hair follicles, and nail beds. As these cells mature and migrate outward, the bound griseofulvin creates a keratin-griseofulvin complex that is resistant to fungal penetration. The existing infected keratin eventually sheds and is replaced by newly synthesized, uninfected tissue.

Main uses

Grifulvin V is indicated for the treatment of dermatophyte infections caused by susceptible species of Trichophyton, Microsporum, and Epidermophyton. It is reserved primarily for fungal conditions where topical antifungal agents are ineffective or impractical due to the depth, extent, or location of the infection.

FDA-approved clinical indications include tinea capitis (ringworm of the scalp), tinea corporis (ringworm of the body), tinea cruris (jock itch), and tinea pedis (athlete’s foot). It is also prescribed for tinea barbae (fungal infection of the beard area) and tinea unguium (onychomycosis of the fingernails or toenails). Grifulvin V is ineffective against bacterial infections, candidiasis (yeast infections), tinea versicolor, or systemic deep mycoses, and should not be utilized for non-susceptible pathogens.

Dosing schedule

The dosing regimen for Grifulvin V must be individualized based on the patient’s age, body weight, liver function, and the specific site of infection. Standard adult dosing typically ranges from 500 mg to 1000 mg per day, administered either as a single daily dose or divided into multiple smaller doses depending on gastrointestinal tolerance and therapeutic requirements.

Duration of therapy is dictated by the rate of tissue turnover at the infected site. Tinea corporis typically requires 2 to 4 weeks of continuous therapy, whereas tinea capitis may necessitate 4 to 6 weeks. Treatment for onychomycosis is significantly longer: fingernail infections generally demand at least 4 months of daily administration, while toenail infections often require 6 months or longer to allow complete regrowth of uninfected nail plates.

What happens in the body

Following oral administration, microsize griseofulvin is absorbed primarily through the upper gastrointestinal tract. The systemic bioavailability of the microsize formulation is substantially influenced by gastric contents; administration alongside fatty foods significantly increases gastrointestinal absorption and peak plasma concentration compared to administration in a fasting state.

Once absorbed into the bloodstream, griseofulvin circulates bound to plasma proteins and distributes to skin, hair, nails, liver, fat, and skeletal muscle. The drug undergoes extensive hepatic metabolism via demethylation and glucuronidation into inactive metabolites, predominantly 6-demethylgriseofulvin. Elimination occurs primarily through renal excretion of metabolites and fecal elimination of unabsorbed drug, with a systemic elimination half-life generally ranging between 9 and 24 hours depending on individual metabolic variability.

Compatibility with other medicines

Grifulvin V engages in several clinically significant drug interactions that require careful medical management and dosage adjustment. It is a known inducer of hepatic cytochrome P450 enzymes, which accelerates the metabolic clearance of concomitantly administered medications.

  • Oral Contraceptive Pills: Griseofulvin enhances the metabolism of estrogen and progestin components, significantly reducing contraceptive efficacy and increasing the risk of breakthrough bleeding or unintended pregnancy. Alternative or supplemental non-hormonal barrier methods are recommended during treatment and for one month following discontinuation.
  • Warfarin and Anticoagulants: Hepatic enzyme induction by griseofulvin decreases the anticoagulant effect of warfarin, necessitating frequent monitoring of prothrombin time/INR and potential anticoagulant dose increases.
  • Barbiturates: Phenobarbital and related barbiturates impair the gastrointestinal absorption of griseofulvin and increase its hepatic clearance, resulting in subtherapeutic serum antifungal concentrations.

Adverse reactions

Treatment with Grifulvin V can produce mild to severe adverse reactions. The most commonly reported side effect is headache, which frequently occurs during early stages of therapy and often diminishes in intensity as treatment continues without requiring drug withdrawal.

Gastrointestinal side effects include nausea, vomiting, epigastric distress, diarrhea, and flatulence. Cutaneous reactions may present as skin rashes, urticaria, or photosensitivity (exaggerated sunburn response upon exposure to ultraviolet light). Central nervous system effects include dizziness, fatigue, insomnia, and confusion. Serious but rare adverse reactions include severe hepatotoxicity, leukopenia, granulocytopenia, and exacerbation of systemic lupus erythematosus.

Important precautions

Grifulvin V is strictly contraindicated in patients with established porphyria, severe hepatocellular insufficiency, or a history of hypersensitivity to griseofulvin. Because griseofulvin has demonstrated teratogenic and embryotoxic effects in animal studies and potential risk in humans, it is contraindicated during pregnancy (Pregnancy Category X). Women of childbearing potential must establish effective non-hormonal contraception, and male patients should refrain from fathering a child during treatment and for six months post-therapy due to potential sperm damage.

For patients undergoing prolonged courses of therapy (exceeding 30 days), baseline and periodic laboratory evaluations are essential. These monitoring procedures should include organ function tests assessing renal, hepatic, and hematopoietic systems. Patients with underlying hepatic impairment or autoimmune disorders require enhanced clinical surveillance.

What to avoid while taking it

Dietary considerations and substance restriction play an essential role during Grifulvin V administration. To maximize drug absorption, oral doses should be taken concurrently with meals or snacks containing moderate to high fat content, such as whole milk, cheese, or butter. Fasting administration results in reduced absorption and inconsistent plasma drug levels.

Alcohol consumption must be strictly limited or avoided entirely throughout treatment. Griseofulvin potentiates the central effects of alcohol and can trigger a disulfiram-like reaction characterized by facial flushing, rapid heart rate, sweating, nausea, and severe headache. Additionally, patients should avoid direct sunlight and artificial ultraviolet exposure due to heightened risk of photosensitivity reactions.

If you skip a dose

Maintaining consistent tissue concentration is critical for therapeutic success with Grifulvin V. If a scheduled dose is missed, it should be taken as soon as remembered on the same day, preferably with food. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the normal dosing schedule resumed.

Patients should never double the dose or take extra medication to make up for a missed administration. Doubling doses increases the risk of adverse gastrointestinal and central nervous system toxicity without enhancing antifungal activity.

Day-to-day use

Successful administration of Grifulvin V involves consistent daily routine adjustments. Taking the medication at the same scheduled time each day alongside a fat-containing meal helps maintain stable drug levels in newly forming keratin structures. Patients taking the liquid oral suspension should shake the container thoroughly prior to each dose to ensure accurate volumetric measurement.

General hygienic measures should accompany pharmacologic treatment to prevent reinfection. Hair and body items, such as combs, towels, socks, and footwear, should be routinely sanitized or replaced. Keeping infected areas clean and thoroughly dry supports the antifungal activity of the systemically deposited medication.

Signs of improvement

Clinical progress with Grifulvin V is typically gradual, as existing infected keratinous tissue must physically grow out and be replaced by healthy tissue. For skin infections, reduction in redness, scaling, and itching may be observed within the first two weeks of treatment.

For hair and scalp infections, reduction in scaling and microscopic clearance of fungal elements indicate treatment response, though visible hair regrowth may require several weeks. In nail infections (onychomycosis), dramatic visible change is usually absent during early treatment; evidence of efficacy appears at the base of the nail bed as a clear, uninfected new nail plate emerges and progressively advances toward the tip.

Common questions

Why must Grifulvin V be taken with fat-containing food?

Microsize griseofulvin is lipophilic (fat-soluble) and exhibits poor water solubility. Consuming fatty foods stimulates bile secretion and enhances the dissolution and mucosal absorption of the drug, leading to significantly higher and more therapeutic blood levels than taking it on an empty stomach.

Can Grifulvin V cause sensitivity to sunlight?

Yes. Photosensitivity is a recognized adverse effect of griseofulvin therapy. Patients may experience severe sunburn or rash after short exposures to natural sunlight or artificial UV radiation. Sunscreen application, protective clothing, and avoidance of tanning beds are recommended during treatment.

Does Grifulvin V interfere with birth control pills?

Yes. Grifulvin V induces hepatic metabolic enzymes that break down contraceptive hormones more rapidly, significantly lowering their concentration in the bloodstream. Women relying on oral, transdermal, or implanted hormonal contraceptives must use reliable non-hormonal barrier methods while taking Grifulvin V and for one month after finishing the medication.

How long does it take for a nail infection to clear completely?

Nail infections require long-term continuous therapy because the medication works by protecting newly growing tissue rather than rapidly sterilizing existing dead nail plate. Fingernails typically require 4 to 6 months of daily treatment, while toenails–which grow much slower–often require 6 to 12 months for full regrowth of a clear nail.

Is it safe to consume alcohol while taking Grifulvin V?

Alcohol should be avoided during Grifulvin V therapy. The drug can cause a disulfiram-like reaction when combined with ethanol, leading to symptoms such as facial flushing, pounding headache, rapid heartbeat, and nausea. Additionally, both alcohol and griseofulvin place metabolic strain on the liver.

Source and disclaimer

Official prescribing information for Grifulvin V is regulated in accordance with US Food and Drug Administration (FDA) guidelines.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

125 mg

,

250mg

Package

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία